Cover
Cover - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Apr. 15, 2024 | Jun. 30, 2023 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Document Period End Date | Dec. 31, 2023 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2023 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity File Number | 333-269188 | ||
Entity Registrant Name | Chromocell Therapeutics Corporation | ||
Entity Central Index Key | 0001919246 | ||
Entity Tax Identification Number | 86-3335449 | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Address, Address Line One | 4400 Route 9 South | ||
Entity Address, Address Line Two | Suite 1000 | ||
Entity Address, City or Town | Freehold | ||
Entity Address, State or Province | NJ | ||
Entity Address, Postal Zip Code | 07728 | ||
City Area Code | (877) | ||
Local Phone Number | 265-8266 | ||
Title of 12(b) Security | Common Stock, $0.0001 par value | ||
Trading Symbol | CHRO | ||
Security Exchange Name | NYSEAMER | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | true | ||
Elected Not To Use the Extended Transition Period | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 0 | ||
Entity Common Stock, Shares Outstanding | 5,877,835 | ||
Document Financial Statement Error Correction [Flag] | true | ||
Document Financial Statement Restatement Recovery Analysis [Flag] | false | ||
Auditor Firm ID | 688 | ||
Auditor Name | Marcum LLP | ||
Auditor Location | Houston, Texas |
BALANCE SHEETS
BALANCE SHEETS - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
CURRENT ASSETS | ||
Cash | $ 96,391 | $ 55,074 |
TOTAL CURRENT ASSETS | 96,391 | 55,074 |
TOTAL ASSETS | 96,391 | 55,074 |
CURRENT LIABILITIES | ||
Accounts payable and accrued expenses | 4,620,925 | 2,993,920 |
Accrued compensation | 645,947 | 221,875 |
Bridge loan, net of debt discount | 316,324 | 435,630 |
Loan payable, net of debt discount | 202,279 | |
Loan payable - related party, net of debt discount | 750,082 | 104,800 |
Due to Chromocell Corporation | 5,386 | 5,386 |
TOTAL CURRENT LIABILITIES | 6,540,943 | 3,761,611 |
TOTAL LIABILITIES | 6,540,943 | 3,761,611 |
STOCKHOLDERS’ DEFICIT | ||
Common stock, $0.001 par value, 100,000,000 shares authorized, 3,914,338 and 1,111,112 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 391 | 111 |
Additional paid in capital | 7,074,646 | 2,432,148 |
Accumulated / parent’s net deficit | (13,519,649) | (6,138,856) |
TOTAL STOCKHOLDERS’ DEFICIT | (6,444,552) | (3,706,537) |
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | 96,391 | 55,074 |
Series A Preferred Stock [Member] | ||
STOCKHOLDERS’ DEFICIT | ||
Preferred stock, value, issued | 60 | 60 |
Series B Preferred Stock [Member] | ||
STOCKHOLDERS’ DEFICIT | ||
Preferred stock, value, issued | ||
Series C Preferred Stock [Member] | ||
STOCKHOLDERS’ DEFICIT | ||
Preferred stock, value, issued |
BALANCE SHEETS (Parenthetical)
BALANCE SHEETS (Parenthetical) - $ / shares | Dec. 31, 2023 | Dec. 31, 2022 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 100,000,000 | 100,000,000 |
Common stock, shares issued | 3,914,338 | 1,111,112 |
Common stock, shares outstanding | 3,914,338 | 1,111,112 |
Series A Preferred Stock [Member] | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 700,000 | 700,000 |
Preferred stock, shares issued | 600,000 | 600,000 |
Preferred stock, shares outstanding | 600,000 | 600,000 |
Series B Preferred Stock [Member] | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 5,000 | 5,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Series C Preferred Stock [Member] | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 5,000 | 5,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
STATEMENTS OF OPERATIONS
STATEMENTS OF OPERATIONS - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
OPERATING EXPENSES | ||
General and administrative expenses | $ 2,738,948 | $ 1,098,848 |
Research and development | 2,579,418 | 391,730 |
Professional fees | 1,543,918 | 827,581 |
Total operating expenses | 6,862,284 | 2,318,159 |
NET LOSS FROM OPERATIONS | (6,862,284) | (2,318,159) |
OTHER (EXPENSE) INCOME | ||
Interest expense | (518,509) | (140,430) |
Total other (expense) income | (518,509) | (140,430) |
Net loss before provision for income taxes | (7,380,793) | (2,458,589) |
Provision for income taxes | ||
NET LOSS | $ (7,380,793) | $ (2,458,589) |
Net loss per common share - basic and diluted | $ 5.78 | $ 5.65 |
Weighted average number of common shares outstanding during the year - basic and diluted | 1,276,543 | 435,312 |
STATEMENT OF CHANGES IN STOCKHO
STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($) | Common Stock [Member] | Preferred Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Beginning balance, value at Dec. 31, 2021 | $ (3,680,267) | $ (3,680,267) | |||
Beginning balance (in shares) at Dec. 31, 2021 | |||||
Fair value of shares issued in contribution agreement | $ 111 | $ 60 | 1,889,400 | 1,900,000 | |
Fair value of shares issued in contribution agreement (in shares) | 10,000,000 | 600,000 | |||
Net contributions from Chromocell Corporation | 422,173 | 422,173 | |||
Stock-based compensation | 110,146 | 110,146 | |||
Net loss | (2,458,589) | (2,458,589) | |||
Ending balance, value at Dec. 31, 2022 | $ 1 | $ 60 | 2,421,719 | (6,138,856) | (3,706,537) |
Ending balance (in shares) at Dec. 31, 2022 | 10,000,000 | 600,000 | |||
Fair value of shares issued in contribution agreement | |||||
Stock-based compensation | 1,733,233 | 1,733,233 | |||
Net loss | (7,380,793) | (7,380,793) | |||
Shares issued for extension of bridge loan | $ 2 | 428,398 | 428,400 | ||
Shares issued for extension of bridge loan (in shares) | 18,892 | ||||
Shares issued for license | $ 38 | 2,225,695 | 2,225,733 | ||
Shares issued for license (in shares) | 384,226 | ||||
Shares issued for cash | $ 253 | 255,159 | 255,412 | ||
Shares issued for cash (in shares) | 2,533,853 | ||||
Shares forfeited | $ (13) | 13 | |||
Shares forfeited (in shares) | (133,745) | ||||
Ending balance, value at Dec. 31, 2023 | $ 391 | $ 60 | $ 7,074,646 | $ (13,519,649) | $ (6,444,552) |
Ending balance (in shares) at Dec. 31, 2023 | 3,914,338 | 600,000 |
STATEMENTS OF CASH FLOWS
STATEMENTS OF CASH FLOWS - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net loss | $ (7,380,793) | $ (2,458,589) |
Adjustments to reconcile net loss to net cash used in operating activities | ||
Amortization of debt discount | 188,119 | 140,430 |
Issuance cost from shares issued on extension of bridge loan | 201,600 | |
Stock-based compensation | 1,733,233 | 110,146 |
Shares issued for license | 2,225,733 | |
Changes in operating assets and liabilities: | ||
Accounts payable and accrued expenses | 1,627,005 | 413,603 |
Accrued compensation | 424,072 | 221,875 |
Due to parent | 5,386 | |
Net Cash Used In Operating Activities | (981,031) | (1,567,149) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Proceeds from loan payable, net of debt discount | 201,008 | |
Proceeds from loan payable - related party, net of debt discount | 565,928 | 100,000 |
Proceeds from bridge loan, net of debt discount | 300,000 | |
Shares issued for cash | 255,412 | |
Net contribution from Chromocell Corporation | 422,173 | |
Advance from Chromocell Corporation | 800,050 | |
Net Cash Provided By Financing Activities | 1,022,348 | 1,622,223 |
NET INCREASE (DECREASE) IN CASH | 41,317 | 55,074 |
CASH AT BEGINNING OF PERIOD | 55,074 | |
CASH AT END OF PERIOD | 96,391 | 55,074 |
Supplemental cash flow information: | ||
Cash paid for income taxes | ||
Cash paid for interest expense | ||
NONCASH INVESTING AND FINANCING ACTIVITIES: | ||
Fair value of shares issued in contribution agreement | 1,900,000 | |
Debt discount from shares issued on extension of bridge loan | 428,400 | |
Shares forfeited | $ 13 |
ORGANIZATION AND NATURE OF BUSI
ORGANIZATION AND NATURE OF BUSINESS | 12 Months Ended |
Dec. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
ORGANIZATION AND NATURE OF BUSINESS | NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS Company Background Chromocell Therapeutics Corporation (“Chromocell” or the “Company”) was incorporated in the State of Delaware on March 19, 2021. On August 10, 2022, the Company entered into that certain Contribution Agreement (the “Contribution Agreement”) with Chromocell Corporation, a Delaware corporation (“Chromocell Holdings”), pursuant to which, effective July 12, 2022 (the “Contribution Date”), Chromocell Holdings contributed all assets and liabilities related to Chromocell Holdings’ historical therapeutic business, including all patents, pre-clinical and Phase I study results and data, and trade secrets related to the CC8464 compound to the Company. (See Note 4) The Company is a development stage life sciences company which improves consumer products and patient lives through breakthrough science and technologies. The Company is focused on the discovery and development of therapeutics through the use of pioneering Chromovert® technology. Chromovert technology enables the Company to use rare cells ideally suited for effective high-throughput screening. The Company’s therapeutics pipeline is currently focused on analgesics and rare diseases, where Chromovert technology has proven highly effective in the rapid identification of potential new drug candidates. The Company has a limited operating history and has not generated revenue from its intended operations. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide along with local, state, and federal governmental policy decisions. A host of factors beyond the Company’s control could cause fluctuations in these conditions. Adverse conditions may include changes in the biotechnology regulatory environment, technological advances that render our technologies obsolete, availability of resources for clinical trials, acceptance of technologies into the medical community, and competition from larger, more well-funded companies. On January 30, 2020, the World Health Organization declared the COVID-19 novel coronavirus outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 coronavirus and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. On May 11, 2023, the United States government declared an end to the COVID-19 pandemic, but it is reasonably possible that future capital raising efforts and additional development of our technologies may still be negatively affected. On February 21, 2024, the Company completed the initial public offering of its Common Stock (the “IPO”) and issued and sold 1,100,000 6.00 |
GOING CONCERN ANALYSIS
GOING CONCERN ANALYSIS | 12 Months Ended |
Dec. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
GOING CONCERN ANALYSIS | NOTE 2 – GOING CONCERN ANALYSIS Management Plans During the year ended December 31, 2023, the Company had a net loss of $ 7,380,793 96,391 The financial statements included in this report do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein. While the Company believes in the viability of our strategy to generate sufficient revenue, control costs, and raise additional funds, when necessary, there can be no assurances to that effect. The Company’s ability to continue as a going concern is dependent upon the ability to implement the business plan, generate sufficient revenues and to control operating expenses. Liquidity and Capital Resources At December 31, 2023, the Company had $ 0.1 million 6.4 million 0.1 million 3.7 million Based on the Company’s current projections, management believes there is substantial doubt about its ability to continue to operate as a going concern and fund its operations through at least the next twelve months following the issuance of these financial statements. While the Company will continue to invest in its business and the development of CC8464 and CT2000, and potentially other molecules, and it is unlikely that the Company will generate product or licensing revenue during the next twelve months. Subsequent to the period, the Company completed its initial public offering, raising $5.7 million, and the Company may need to raise additional funds through either strategic partnerships or the capital markets. However, there is no assurance that the Company will be able to raise such additional funds on acceptable terms, if at all. If the Company raises additional funds by issuing securities, existing stockholders may be diluted. If adequate funds are not available and expenditures exceed the Company’s current expectations, the Company may be required to curtail its operations or other business activities or obtain funds through arrangements with strategic partners or others that may require the Company to relinquish rights to certain technologies or potential markets. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation Prior to the execution of the Contribution Agreement between Chromocell and Chromocell Holdings (see Note 4), Chromocell did not constitute a separate legal entity or group and as such, stand-alone financial statements were not previously prepared for the Company. As a result, carve-out financial statements for Chromocell were prepared for the year ended December 31, 2022, which include all of Chromocell’s operations which have been conducted within Chromocell Holdings, which also has other activities. These financial statements have been prepared on a stand-alone basis derived from the financial statements and related accounting records of Chromocell Holdings. The accompanying carve-out financial statements present the historical financial position, results of operations, changes in net assets and cash flows of the Company as it was historically conducted, as more fully described below in Note 4. The financial information in these financial statements does not necessarily include all the expenses that would have been incurred had the Company operated as a separate stand-alone entity and may not reflect results of operations, financial position and cash flows had the Company been a stand-alone company during the year ended September 30, 2023. With the execution of the Contribution Agreement on August 12, 2022, effective for the reporting period ended December 31, 2022 and all future reporting periods, the financial statements reflect Chromocell as a stand-alone entity. For all periods, the Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, realization of long-lived assets, valuation of deferred income taxes, unrealized tax positions and business combination accounting. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2023 and December 31, 2022, the Company did not have any cash equivalents. As of December 31, 2023 and December 31, 2022, the Company did not have any deposits in excess of Federally insured limits. Research and Development We incur research and development costs during the process of researching and developing our technologies and future offerings. We expense these costs as incurred unless such costs qualify for capitalization under applicable guidance. The Company reviews acquired R&D and licenses to determine if they should be capitalized or expensed under U.S. GAAP standards. Below is a disaggregation of R&D expenses: For the Year Ended For the Year Ended December 31, 2023 December 31, 2022 Consultant $ 68,900 $ 86,802 Lab Gas — 13,871 Lab Cell Storage 48,572 62,197 Chemistry Manufacturing and Controls (“CMC”) — 3,800 IP Services 2,461,946 225,060 Total $ 2,579,418 $ 391,730 Fair Value Measurements and Fair Value of Financial Instruments The Company adopted FASB ASC Topic 820, Fair Value Measurements (“ASC Topic 820”). ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: ● Level 1 Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. ● Level 2 Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. ● Level 3 Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820. Due to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the balance sheet dates. Stock-Based Compensation The Company accounts for stock-based compensation costs under the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock-based compensation expense recognized includes the compensation cost for all stock-based payments granted to employees, officers, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC 718 is also applied to awards modified, repurchased, or cancelled during the periods reported. Stock-based compensation is recognized as expense over the employee’s requisite vesting period and over the nonemployee’s period of providing goods or services. Pursuant to ASC 718, the Company can elect to either recognize the expenses on a straight-line or graded basis and has elected to do so under the straight-line basis. Basic and Diluted Net Loss per Common Share Basic loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As of December 31, 2023, 197,560 stock options were excluded from dilutive earnings per share as their effects were anti-dilutive. Income Taxes The Company accounts for income taxes pursuant to the provision of ASC 740 “Accounting for Income Taxes,” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized. The Company follows the provision of the ASC 740 related to Accounting for Uncertain Income Tax Position. When tax returns are filed, it is more likely than not that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is most likely that not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions will more likely than not be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits. The federal and state income tax returns of the Company are subject to examination by the Internal Revenue Service and state taxing authorities, generally for three years after they were filed. The Company is in the process of filing the tax returns for the 2023 year. After review of the prior year financial statements and the results of operations through December 31, 2023, the Company has recorded a full valuation allowance on its deferred tax asset. Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which was codified in Accounting Standards Codification (“ASC”) 326, Financial Instruments — Credit Losses (“ASC 326”). The standard changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. Because the Company is a smaller reporting company based on the most recent determination as of November 15, 2019, ASC 326 became effective for the Company for fiscal years beginning after December 15, 2022. As such, the Company adopted ASC 326 effective January 1, 2023, utilizing the modified retrospective transition method. Upon adoption, the Company updated its impairment model to utilize a forward-looking current expected credit losses (“CECL”) model in place of the incurred loss methodology for financial instruments measured at amortized cost, primarily including its accounts receivable and contract asset. In relation to available-for-sale (“AFS”) debt securities, the guidance eliminates the concept of “other-than-temporary” impairment, and instead focuses on determining whether any impairment is a result of a credit loss or other factors. The adoption of ASC 326 did not have a material impact on our financial statements as of the adoption date. In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature and convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt and will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that is within the scope of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and treasury stock method will be no longer available. ASU 2020-06 is applicable for fiscal years beginning after December 15, 2022, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The adoption of this ASU did not have a material effect on the Company’s financial statements. Recently Issued Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity’s effective tax rate reconciliation, as well as information related to income taxes paid to enhance the transparency and decision usefulness of income tax disclosures. This ASU will be effective for the annual period ending December 31, 2025. The Company is currently evaluating the timing and impacts of adoption of this ASU. Subsequent Events The Company has evaluated all transactions through the date the financial statements were issued for subsequent event disclosure consideration. |
CARVE-OUT CRITERIA AND ASSUMPTI
CARVE-OUT CRITERIA AND ASSUMPTIONS | 12 Months Ended |
Dec. 31, 2023 | |
Carve-out Criteria And Assumptions | |
CARVE-OUT CRITERIA AND ASSUMPTIONS | NOTE 4 – CARVE-OUT CRITERIA AND ASSUMPTIONS The carve-out statements of operations, as set forth above for the year ended December 31, 2022 and which was the subject of the statement of operations contained herein, reflect direct revenues and expenses and allocations of indirect expenses related to certain support functions that were provided on a centralized basis by Chromocell Holdings ● Employment related expenses – allocated all Chromocell direct salaries and an allocation of headquarters salaries based on headcounts. ● General and administrative expenses and Professional fees – allocated all direct Chromocell related expenses and corporate expense have been allocated to reflect the utilization of those corporate services by the Company. ● Research and development expenses – all Research and development expenses are direct Chromocell expenses. ● Rent and related expenses and security deposits – applied a ratio based on floor space used by Chromocell. ● Long lived assets – long lived assets are owned by Chromocell Holdings Inc and under shared use by its components including the Company. Operating expenses are allocated that reflect the usage of the long-lived asset by the Company. ● Accounts payable and accrued expenses – allocated all direct Chromocell liabilities and an allocation corporate expense reflecting the utilization of those corporate services by the Company. ● PPP loan and PPP loan forgiveness – allocated to reflect the utilization of the proceeds by the Company. ● Bridge loan – the bridge loan was fully allocated to the Company. (See Note 6) Chromocell Holdings uses a centralized approach to cash management of its operations. Any cash excess over comprehensive income earned by the Company were transferred to Chromocell Holdings through “net parent investment.” Accordingly, none of the Chromocell Holdings cash and cash equivalents, have been assigned to the Company in the carve-out combined financial statements. As these carve-out financial statements present a portion of the business of Chromocell Holdings, which does not constitute a separate legal entity for the purposes of carve-out financial statements, the net assets of the Chromocell Holdings have been presented as parent’s net deficit. Except for the PPP loan, Chromocell Holdings third-party bank loans, related party loans and the related interest expense have not been included in the carve-out financial statements for any of the periods presented. Chromocell is not the legal obligor on those loans, and they were not directly attributable to the Chromocell operations. As the lease is held by Chromocell Holdings, the Company does not have the right to control the use of the space being leased and only shares the space. As such, there is no lease liability or right of use asset recorded for Chromocell. Management believes the assumptions underlying the carve-out, including the assumptions regarding allocation of expenses, are reasonable. For the year ended December 31, 2023, the financial statements reflect Chromocell as a stand-alone entity. Contribution Agreement On August 10, 2022, the Company and Chromocell Holdings Corporation (“Chromocell Holdings”) entered into the Contribution Agreement effecting (1) the contribution by Chromocell Holdings to the Company of assets related to Chromocell Holding’s Therapeutics Business, including all intellectual property related to Chromocell Holding’s NaV1.7 program and its clinical-stage CC8464 lead compound, (2) assumption by the Company of direct As part of the contribution agreement, Chromocell Holdings transferred to the Company assets related to Chromocell Holding’s Therapeutics Business, including all the patents and intellectual property related to Chromocell Holding’s NaV1.7 program and its clinical-stage CC8464 lead compound. The Company analyzed the transaction for common control pursuant to ASC 805-50. While the term “common control” is not defined, there are examples in the Transactions between Entities under Common Control Subsection that, among others, indicates that “an entity [that] charters a newly formed entity and then transfers some or all of its assets to the newly chartered entity” is an example of a transaction involving common control, yielding recordation of assets at the transferors’ historical cost basis. This directly mirrors the terms underlying the Contribution Agreement whereby Holdings established the Company as wholly owned subsidiary and transferred the Intangibles in return to 100% of the stock of the Company. Further, Staff Accounting Bulletin (“SAB”) Topic 5G dictates that “transfers of nonmonetary assets to a company by its promoters or shareholders in exchange for stock prior to or at the time of the company’s initial public offering normally should be recorded at the transferors’ historical cost basis determined under GAAP.” As a result, pursuant to ASC 805-50 and SAB Topic 5G, the Company recorded the net assets acquired at historical value when the Contribution Agreement was executed. All of the assets, liabilities and results of operations of the Company as of and for the periods prior to the Contribution Date were identified based on the assets contributed to the Company from Chromocell Holdings. Management believes the assumptions underlying the Company’s carve-out financial statements are reasonable. Nevertheless, the financial statements may not include all of the actual expenses that would have been incurred had the Company operated as a standalone company during the periods presented, and may not reflect the Company’s results of operations, financial position and cash flows had the Company operated as a standalone company during the periods presented. Actual costs that would have been incurred if the Company had operated as a standalone company would depend on multiple factors, including organizational structure and strategic decisions made in various areas, including information technology and infrastructure. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 12 Months Ended |
Dec. 31, 2023 | |
Related Party Transactions [Abstract] | |
RELATED PARTY TRANSACTIONS | NOTE 5 – RELATED PARTY TRANSACTIONS Employment Agreement The Company entered into an employment agreement with Christian Kopfli, dated January 10, 2023. Pursuant to such agreement, Mr. Kopfli agreed to serve as the Company’s Chief Executive Officer and Vice-Chairman of its Board of Directors (the “Board”) in consideration for an annualized salary of $275,000, payable in cash at the rate of $5,000 per month (a minimum of $1,125 per week), with the remainder accrued and paid as of the earliest of a sale or liquidation of the Company, the Company’s bankruptcy or three days after the approval by the Board of a funded budget with appropriately established milestones subsequent to the effective date of a Form S-1 registration statement (“Post-registration Approval”). Mr. Kopfli also agreed, as of Post-registration Approval, to resign as Chief Executive Officer of Chromocell Corporation although he may continue service on the Board of Directors of Chromocell Corporation, including as its Board Chairperson. The employment agreement provides that Mr. Kopfli receive an option to acquire 22,223 shares of the Company’s common stock Pursuant to Mr. Kopfli’s employment agreement, in the event he is involuntarily terminated by the Company other than for “Cause” or if he resigns for “Good Reason,” he is entitled to receive (i) six months of salary at the same rate existing immediately prior to his termination, (ii) his target bonus, if performance goals and objectives have been established for the year and prorated for the period of service, and (iii) six months of additional vesting credit with respect to any outstanding time-based equity awards. “Cause” and “Good Reason” are each defined in the employment agreement. Finally, Mr. Kopfli agrees to certain non-solicitation and non-competition provisions for a period of 12 months following termination and to certain confidentiality obligations. Additional terms and conditions are set forth in the employment agreement. On July 28, 2023, the Company amended and restated Mr. Kopfli’s employment agreement whereby Mr. Kopfli’s title changed to Vice Chairman and Chief Strategy Officer. Other terms and conditions of the amended and restated employment agreement remain the same. On November 27, 2023, Mr. Kopfli was removed from the Company’s Board by the stockholders having a majority of the number of votes necessary to take such action. Mr. Kopfli was then terminated from his position as Vice Chairman and Chief Strategy Officer by the Company for “Cause”, as defined in Mr. Kopfli’s employment agreement, effective December 1, 2023. On February 14, 2024, the Board received a demand letter from an attorney representing Chromocell Holdings and Mr. Kopfli. Mr. Kopfli alleges an improper termination for “cause” and seeks monetary damages in connection therewith in the amount of $479,169. Of the $479,169 asserted by Mr. Kopfli, as of December 31, 2023, the Company has accrued $363,091 in compensation expenses associated with Mr. Kopfli’s prior employment with the Company. To the extent Mr. Kopfli is successful in his assertions, the Company will pay any amounts owed thereunder from future working capital reserves; however, the Company believe the assertions made by Mr. Kopfli are without merit and intend to vigorously defend the matter. Consultant Agreement The Company entered into a Consultant Agreement with Camden Capital LLC, dated January 10, 2023. This consultant agreement replaces an agreement with Mr. Francis Knuettel II dated June 2, 2022, and pursuant to the agreement, Camden Capital LLC agreed to provide the services of Mr. Knuettel, who is serving as the Company’s Chief Financial and Strategy Officer, Treasurer and Secretary. Under the consultant agreement with Camden Capital LLC, the Company accrued a consulting fee for the period June 6, 2022 through August 31, 2022 of $10,000 per month and effective September 1, 2022, began to accrue a consulting fee of $20,000 per month, payable in cash at the rate of $5,000 per month (a minimum of $1,125 per week), with the remainder accrued. The expenses for these were recognized in the periods that they occurred. All accrued consulting fees are payable as of the earliest of a sale or liquidation of the Company, the Company’s bankruptcy or three days after Post-registration Approval. The consulting agreement provides for the following equity awards to Camden Capital LLC: (i) an option, awarded as of January 10, 2023, to acquire 22,223 shares of the Company’s common stock, vesting quarterly over 10 quarters beginning on October 1, 2022 , with the option having an exercise price equal to the fair market value of the Company’s common stock on the date of grant and expiring on the 10th anniversary of the date of grant; (ii) an option, awarded as of January 10, 2023, to acquire 2,778 shares of the Company’s common stock, vesting 100% upon the sooner of the sale of the Company or Post-registration Approval, with the option having an exercise price equal to the fair market value of the Company’s common stock on the date of grant and expiring on the 10th anniversary of the date of grant; and (iii) an RSU, awarded as of January 10, 2023, of 16,667 shares of the Company’s common stock, vesting 100% on the day after the first trading window that opens after Post-registration Approval. The Company began recognizing the vesting expense for the options during the year ended December 31, 2022. The consultant agreement contemplates an additional consulting fee, as determined by the Board. The potential additional consulting fee is 50% of the annualized consulting fee and will be based on achievement of performance goals and objectives established by the Board in concert with Mr. Knuettel in January of each year. The Board may increase the potential additional consulting fee in recognition of performance in excess of the performance objectives. Any amount shall only be paid if Camden Capital LLC continues to provide consulting services to the Company as of the date of payment, which will be no later than March 15 of the year following the year to which the additional consulting fee relates. Any additional consulting fee for 2022 is payable solely at the Board’s discretion. Pursuant to the consultant agreement, in the event the relationship with Camden Capital LLC is involuntarily terminated by the Company other than for “Cause” or if Camden Capital LLC terminates the relationship for “Good Reason,” Camden Capital LLC is entitled to receive (i) six months of consulting fees at the same rate existing immediately prior to termination, (ii) a potential additional consulting fee, if performance goals and objectives have been established for the year and prorated for the period of service, and (iii) six months of additional vesting credit with respect to any outstanding time-based equity awards. “Cause” and “Good Reason” are each defined in the consulting agreement. Finally, Camden Capital LLC and Mr. Knuettel agree to certain non-solicitation and non-competition provisions for a period of 12 months following termination of the relationship and to certain confidentiality obligations. Additional terms and conditions are set forth in the consulting agreement. Director Note On December 6, 2022, the Company and Mr. Todd Davis, one of the Company’s directors, entered into the Director Note for $175,000. The Director Note has an original issuance discount of $75,000, and matures on December 31, 2023, or, if earlier to occur, upon the closing of an underwritten offering of securities resulting in at least $15 million in gross proceeds. April and September Bridge Financings On April 17, 2023 and September 1, 2023, the Company entered into bridge notes, the investors in which were almost entirely existing investors. Related party investors in the April Bridge Financing include Chromocell Holdings, Boswell Prayer Ltd., Motif Pharmaceuticals Ltd, Aperture Healthcare Ventures Ltd., MDB Merchants Park LLC, Balmoral Financial Group LLC and AME EQUITIES LLC (each a related party based on share ownership in excess of 5% or resulting from a principal at one of the entities being on the Company’s board of directors). All of these investors, except Chromocell Holdings, also participated in the September Bridge Financing. Due to Chromocell Corporation As of December 31, 2023, the Company had a $ 5,386 Side Letter to the Contribution Agreement and Issuance of Series C Convertible Redeemable Preferred Stock On August 2, 2023, the Company entered into a side letter to the Contribution Agreement (the “Holdings Side Letter”) with Chromocell Holdings. Pursuant to the side letter, upon closing of the Company’s IPO: (a) Chromocell Holdings re-assumed all $1.6 million in direct liabilities previously assumed by the Company in accordance with the Contribution Agreement, (b) Chromocell Holdings waived the Company’s obligations to make a cash payment in the amount of $0.6 million to Chromocell Holdings, and (c) in consideration thereof, the Company issued to Chromocell Holdings 2,600 shares of Series C Convertible Redeemable Preferred Stock of the Company, par value of $0.0001 per share (the “Series C Preferred Stock”). The Series C Preferred Stock has a liquidation preference of $ 1,000 |
NOTES PAYABLE
NOTES PAYABLE | 12 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
NOTES PAYABLE | NOTE 6 – NOTES PAYABLE Investor Note On February 4, 2022, the Company entered into a note payable for $ 450,000 150,000 50 February 3, 2023 14,370 135,630 On February 27, 2023, the Investor Note agreement was amended. The maturity date was extended from its original due date of February 3, 2023 to May 15, 2023, in return for the Company agreeing to pay 2% per month in accrued interest and the third party agreeing to settle its outstanding debt, including accrued interests in shares of common stock at the IPO. Accrued interest and related interest expense totaled $98,056 for the years ended December 31, 2023, compared to $0 for year ended December 31, 2022. On June 23, 2023, the Company entered into a side letter with the holder of the Investor Note pursuant to which the Company (i) amended and restated the Investor Note to extend the maturity date to August 15, 2023 and (ii) in consideration therefor, issued to such holder 50,000 shares of common stock. The Company determined that this extension qualified as a modification of the Investor Note rather than an extinguishment. The Company recorded an expense of $126,000 from the issuance of the 556 shares of common stock based on a share price of $22.68. The $22.68 share price was based on a third-party valuation of the company’s common stock, with certain adjustments as set forth below in detail in Note 7 – Stockholders’ Equity. This expense was recorded to interest expense on the Company’s statement of operations for the year ended December 31, 2023. On August 17, 2023, the Company entered into a second side letter with the holder of the Investor Note (the “August Investor Note Side Letter” and, together with the June Investor Note Side Letter, the “Investor Note Side Letters”) pursuant to which the Company (i) amended and restated the Investor Note to extend the maturity date to September 30, 2023 and (ii) in consideration therefor, issued to such holder 30,000 450,000 In addition, pursuant to the Investor Note Side Letters, the Company agreed to register the 8,890 shares of Common Stock (5,556 issued for the June 23, 2023 side letter, and 3,334 issued for the August 17, 2023 side letter) for resale. The Company recorded an expense of $75,600 from the issuance of the 3,333 shares of common stock based on a share price of $22.68. The $22.68 share price was based on a third-party valuation of the company’s common stock, with certain adjustments Effective October 10, 2023, the Company entered into a side letter with the Holder of the Investor Note, which extended the maturity date of the Investor Note to November 14, 2023 and the Company issued to the Holder of the Investor Note 3,334 75,600 3,333 22.68 Effective November 13, 2023, the Company entered into another side letter with the holder of the Investor Note pursuant to which the Company (i) amended and restated the Investor Note to extend the maturity date to January 31, 2024, and (ii) in consideration therefor, agreed to issue to such Holder of the Investor Note 3,334 75,600 3,334 22.68 Effective January 30, 2024, the Company entered into another side letter with the holder of the Investor Note (the “January Investor Note Side Letter”) pursuant to which the Company (i) amended and restated the Investor Note to extend the maturity date to February 29, 2024, and (ii) in consideration therefor, agreed to issue to such Holder of the Investor Note 77,778 Director Note On December 6, 2022, the Company and Mr. Todd Davis, one of the Company’s directors, entered into a note payable agreement (the “Director Note”) for $ 175,000 75,000 15 72,000 On December 28, 2023, the Company entered into an amendment to the Director Note, which extended the maturity date to February 29, 2024. The Director Note was exchanged for common stock at the time of the Company’s IPO. April Bridge Financing On April 17, 2023, the Company entered into a bridge loan for working capital purposes, with various accredited investors, all of whom are pre-existing stockholders, in the aggregate principal amount of $393,808 (the “April Bridge Financing”). During the three months ended March 31, 2023, the Company received $166,903 in Advances from certain participating investors. Such Advances accrued interest at a rate of 8% per annum until close of the April Bridge Financing on April 17, 2023, for a total of $1,870 in aggregate interest on all Advances. On October 12, 2023, the Company entered into a first amendment to the senior secured convertible notes in the April Bridge Financing, which extended the maturity of the notes to November 1, 2023. On October 24, 2023, the Company entered into a second amendment to the senior secured convertible notes in the April Bridge Financing, which extended the maturity of the notes to November 14, 2023. On November 13, 2023, the Company entered into a third amendment to the senior secured convertible notes in the April Bridge Financing, which further extended the maturity of the notes to February 29, 2024. September Bridge Financing On September 1, 2023, the Company entered into a bridge loan for working capital purposes, with various accredited investors, certain of which are pre-existing stockholders, in the aggregate principal amount of $ 198,128 October Promissory Notes On October 12, 2023, the Company and four existing investors entered into promissory notes (the “October Promissory Notes”) with an aggregate face amount of $ 210,000 175,000 |
STOCKHOLDERS_ EQUITY
STOCKHOLDERS’ EQUITY | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
STOCKHOLDERS’ EQUITY | NOTE 7 – STOCKHOLDERS’ EQUITY Stock Split On February 21, 2024, the Company effected a 9-for-1 reverse stock split. All share and per share amounts have been retrospectively adjusted for the reverse stock split. Share Forfeiture Pursuant to the terms of the April Bridge Financing, Chromocell Holdings forfeited 1,203,704 Standby Investor Side letter On October 11, 2023, the Company entered into a securities purchase agreement with an institutional investor (the “Standby Investor”), pursuant to which (i) the Standby Investor agreed to purchase, upon close of the IPO and at the Company’s election, an aggregate of up to 750 0.0001 1,000 in consideration therefor, the Company would issue upon close of the IPO, and regardless of whether the Company would have issued any shares of Series B Preferred Stock, an aggregate of 4,167 shares (such shares, the “Standby Shares”) of Common Stock to the Standby Investor (such agreement, the “Series B Securities Purchase Agreement”). Effective November 13, 2023, the Company entered into a side letter with the Standby Investor (the “Standby Investor Side Letter”), pursuant to which it (i) waived in full the Standby Investor’s obligation to fund the aggregate amount to be paid for the Series B Preferred Stock to be purchased under the Series B Securities Purchase Agreement and (ii) agreed to continue to have the obligation to issue the full amount of the Standby Shares upon the closing of the IPO. The Company and the Standby Investor also agreed to terminate each of their obligations solely with respect to the Series B Preferred Stock under the Series B Securities Purchase Agreement and that certain Registration Rights Agreement between the Company and the Standby Investor, which was required to be delivered pursuant to the Series B Securities Purchase Agreement. Rights Offering On November 22, 2023, the Company commenced a rights offering (the “Rights Offering”) pursuant to which the Company distributed non-transferable subscription rights (“Subscription Rights”) to each holder of its Common Stock held as of 5:00 p.m. Eastern Standard Time on November 22, 2023, the record date for the Rights Offering (the “Rights Offering Record Date”). The Subscription Rights could be exercised at any time during the subscription period, which commenced on November 22, 2023 and expired at 5:00 p.m., Eastern Standard Time, on December 1, 2023. Each Subscription Right entitled the eligible holder to purchase up to three shares of the Company’s Common Stock at a price per whole share of Common Stock of $ 0.1008 2,533,853 255,412 Options On January 10, 2023, the Company granted options to acquire 50,002 shares of the Company’s common stock to employees and consultants of the Company pursuant to their employment or consulting agreements. These options had a grant date fair value of $1,122,244. These options have an exercise price of $22.68, a term of 10 years, and vest quarterly over ten quarters, with such vesting commencing on October 1, 2022. On January 10, 2023, the Company granted an option to acquire 2,778 shares of the Company’s common stock to a consultant of the Company pursuant to their consulting agreements. This option had a grant date fair value of $62,336. This option has an exercise price of $22.68, a term of 10 years, and vests upon the IPO or sale of the Company. On January 10, 2023, the Company issued a total of 88,891 options to purchase shares of the Company’s common stock to several of its directors, pursuant to their continued service as a director. These options had a grant date fair value of $1,994,768. These options have an exercise price of $22.68, a term of 10 years, and 66,668 of these options will vest over 2.5 years commencing on January 10, 2023, and 22,223 of the options will vest upon the Company’s establishment of a second clinical program, which shall include an acquisition or entrance into a joint venture. During the year ended December 31, 2023, the Company recorded $1,097,122 in stock compensation for the options that vested during the period. On March 9, 2023, the Company issued an option to acquire 15,000 shares of the Company’s common stock to a director, pursuant to their continued service as a director. This option had a grant date fair value of $336,606. This option has an exercise price of $22.68, a term of 10 years, and will vest over 2.25 years commencing on March 9, 2023. On May 15, 2023, the Company issued an option to acquire 27,778 shares of the Company’s common stock to a director, pursuant to their continued service as a director. This option had a grant date fair value of $623,057. This option has an exercise price of $22.68, a term of 10 years, and vests upon the IPO or sale of the Company. On May 15, 2023, the Company issued an option to acquire 24,223 shares of the Company’s common stock to a director, pursuant to their continued service as a director. This option had a grant date fair value of $543,306. This option has an exercise price of $22.68, a term of 10 years, and will vest over 3 years. During the year ended December 31, 2023, the fair value of each stock option granted was estimated using the Black-Scholes Option Pricing Model using the following inputs: Exercise price $ 22.68 Expected dividend yield 0 % Risk free interest rate 3.50 3.93 % Expected life in years 10 Expected volatility 157 158 % The risk-free interest rate assumption for options granted is based upon observed interest rates on the United States Government Bond Equivalent Yield appropriate for the expected term of the options. With certain adjustments outlined below, the Company based its determination of the underlying fair value of the Company’s common stock on the findings of an independent third party engaged by the Company to determine the fair value of the Company’s intellectual property. The Company had the analysis conducted in conjunction with the Contribution Agreement, which was executed on August 10, 2022. The analysis determined that the fair value of the Company’s intellectual property was $ 44.8 1,187,302 600,000 37.71 Schedule the fair value of the Company’s intellectual property Value of intellectual property $ 44.8 Common shares outstanding (as converted) 1,187,302 Value per common share $ 37.71 Illiquidity discount 20 % Minority discount 20 % Fair value of the common stock $ 22.68 The Company determined the expected volatility assumption for options granted using the historical volatility of comparable public companies’ common stock. The Company will continue to monitor peer companies and other relevant factors used to measure expected volatility for future option grants, until such time that the Company’s common stock has enough market history to use historical volatility. The dividend yield assumption for options granted is based on the Company’s history and expectation of dividend payouts. The Company has never declared nor paid any cash dividends on its common stock, and the Company does not anticipate paying any cash dividends in the foreseeable future. The Company recognizes option forfeitures as they occur as there is insufficient historical data to accurately determine future forfeiture rates. The following is an analysis of the stock option grant activity: Weighted Weighted Number Exercise Price Remaining Stock Options Outstanding December 31, 2022 50,002 $ 22.68 9.76 Granted 158,670 $ 22.68 9.16 Expired (11,112 ) $ 22.68 — Exercised — $ — — Outstanding December 31, 2023 197,560 $ 22.68 9.08 Exercisable December 31, 2023 84,131 $ 22.68 8.98 A summary of the status of the Company’s nonvested options as of December 31, 2023, and changes during the year ended December 31, 2023, is presented below: Non-vested Options Options Weighted- Non-vested at December 31, 2022 45,556 $ 22.68 Granted 158,670 $ 22.68 Vested (90,797 ) $ 22.68 Forfeited — $ — Non-vested at December 31, 2023 113,429 $ 22.68 The total number of options granted during the year ended December 31, 2023 and 2022 was 197,560 0 22.68 0 The Company recognized stock-based compensation expense related to option vesting amortization of $ 1,733,233 110,146 As of December 31, 2023, the unamortized stock option expense was $ 1,854,280 2.91 On June 23, 2023, the Company and Camden Capital LLC amended and restated the Consultant Agreement by entering into an Amended and Restated Consultant Agreement, whereby the RSU for 16,667 shares of common stock was cancelled, and the Company agreed to grant Camden Capital LLC an option to acquire 27,778 shares of common stock within 30 days of the closing of the IPO. As of June 23, 2023, such RSU for 16,667 shares of common stock had not vested, and no expense was recorded on the Company’s financial statements. |
LICENSE AGREEMENT
LICENSE AGREEMENT | 12 Months Ended |
Dec. 31, 2023 | |
License Agreement | |
LICENSE AGREEMENT | NOTE 8 – LICENSE AGREEMENT Benuvia License Agreement On December 23, 2023, the Company entered into an exclusive licensing agreement (the “Benuvia License Agreement”) with Benuvia Operations, LLC (“Benuvia”) for a sublingual formulation of a Diclofenac spray for the treatment of acute pain, a Rizatriptan sublingual spray formulation and an Ondansetron sublingual spray formulation (collectively, the “Spray Formulations”), diversifying its pipeline of non-opioid pain treatment therapies, while adding therapeutic options for related conditions. The Diclofenac Spray Formulation is patented and has started clinical development in human volunteers. Under the terms of the Benuvia License Agreement, Benuvia will be responsible for the manufacturing and supply of the Spray Formulations, but the Company will have exclusive, worldwide rights to develop, commercialize and distribute the Spray Formulations. In connection with the Benuvia License Agreement, the Company agreed to pay Benuvia a 6.5% royalty on net sales of the Spray Formulations for a period of up to 15 years from the date of the first commercial sale of any of the Spray Formulations. In addition, on December 23, 2023, the Company entered into a stock issuance agreement with Benuvia pursuant to which the Company agreed to issue Benuvia 384,226 shares of the Company’s Common Stock. The issuance of 384,226 2.2 million |
INCOME TAX
INCOME TAX | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
INCOME TAX | NOTE 9 – INCOME TAX The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The Company used the separate return method for the preparation of the income tax provision. For the years ended December 31, 2023 and 2022, there was no income tax provision recorded. The tax benefit was added to the net operating loss to which a full valuation allowance was applied. A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows: 2023 2023 Income taxes at U.S. statutory rate 19.11 % 19.11 % Income taxes at state rate 9.00 % 9.00 % Change in valuation allowance (28.11 )% (28.11 )% Total provision for income taxes — % — % Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company’s deferred tax assets and liabilities as of December 31, 2023 and 2022 are comprised of the following: December 31, 2023 2022 Deferred tax assets Net operating loss carryforwards $ 2,248,163 $ 1,763,875 Stock-based compensation 518,174 30,962 Accrued compensation 181,576 62,369 Capitalized organizational costs 22,016 — Capitalized intellectual property costs 620,440 — Interest expense limitation 36,202 — Total deferred tax assets 3,626,571 1,857,206 Valuation allowance (3,626,571 ) (1,857,206 ) Net deferred tax assets — — Deferred tax liabilities Total deferred tax liabilities — — Net deferred taxes $ — $ — For the years ended December 31, 2023 and 2022, the Company recorded a full valuation allowance of its deferred tax assets. The previously reported deferred tax components, including the valuation allowance, totalling $ 4,053,204 The Company has a net operating loss carryforward for federal tax purposes totalling approximately $ 8.0 million 8.0 million Utilization of NOL and tax credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by the Internal Revenue Code (the “Code”), as amended, as well as similar state provisions. In general, an “ownership change” as defined by the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 12 Months Ended |
Dec. 31, 2023 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | NOTE 10 – SUBSEQUENT EVENTS Initial Public Offering On February 21, 2024, the Company consummated the IPO and issued and sold 1,100,000 6.00 5.7 Bridge Financing Note Amendments and Recission Agreement On February 8, 2024, the Company and certain affiliates of A.G.P./Alliance Global Partners (“A.G.P.”) entered into amendments to the senior secured convertible notes issued to such affiliates of the A.G.P. in the April Bridge Financing and September Bridge Financing to remove the automatic conversion features from such notes (the “Bridge Financing Note Amendments”). Under the Bridge Financing Note Amendments, both notes issued in the April Bridge Financing and the September Bridge Financing have a maturity date of March 1, 2024, and the full principal amount of both notes and any accrued interest thereon shall be payable solely in cash upon the consummation of the IPO. Both notes have an annual interest rate of 8%, which accrues daily, and is calculated on the basis of a 360-day year (consisting of twelve 30 calendar day periods), giving an effective interest rate of 8.3%. On February 10, 2024, the Company entered into a Stock Rescission Agreement with certain affiliates of A.G.P. (the “Stock Rescission Agreement” and, together with the Bridge Financing Note Amendments, the “Representative Affiliate Transactions”), pursuant to which the Company rescinded 111,129 shares of Common Stock held by such affiliates of A.G.P. and agreed to refund an aggregate of $91,513 paid by such affiliates of A.G.P. in consideration therefor within 30 days of the effective date of the Stock Rescission Agreement. Amendment to Investor Note Effective January 30, 2024, the Company entered into another side letter with the holder of the Investor Note (the “January Investor Note Side Letter”) pursuant to which the Company (i) amended and restated the Investor Note to extend the maturity date to February 29, 2024, and (ii) in consideration therefor, agreed to issue to such Holder of the Investor Note 77,778 shares of Common Stock on the earlier to occur of the IPO or February 29, 2024. Appointment of Francis Knuettel II as Chief Executive Officer Effective March 13, 2024, our board of directors has appointed Francis Knuettel II as Chief Executive Officer of the Company. Mr. Knuettel will serve as the Company’s Chief Executive Officer until a successor is duly elected and qualified, unless sooner removed. In addition to his role as Chief Executive Officer of the Company, Mr. Knuettel will continue to serve in his capacity as Chief Financial Officer, Treasurer and Secretary of the Company. Complaint Filed by New Jersey Economic Development Authority On April 9, 2024, we received correspondence notifying us of an Entry of Default Notice, filed on April 8, 2024, against “Chromocell Corporation d/b/a Chromocell Therapeutics” in the matter New Jersey Economic Development Authority v. Chromocell Corporation, et al. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation Prior to the execution of the Contribution Agreement between Chromocell and Chromocell Holdings (see Note 4), Chromocell did not constitute a separate legal entity or group and as such, stand-alone financial statements were not previously prepared for the Company. As a result, carve-out financial statements for Chromocell were prepared for the year ended December 31, 2022, which include all of Chromocell’s operations which have been conducted within Chromocell Holdings, which also has other activities. These financial statements have been prepared on a stand-alone basis derived from the financial statements and related accounting records of Chromocell Holdings. The accompanying carve-out financial statements present the historical financial position, results of operations, changes in net assets and cash flows of the Company as it was historically conducted, as more fully described below in Note 4. The financial information in these financial statements does not necessarily include all the expenses that would have been incurred had the Company operated as a separate stand-alone entity and may not reflect results of operations, financial position and cash flows had the Company been a stand-alone company during the year ended September 30, 2023. With the execution of the Contribution Agreement on August 12, 2022, effective for the reporting period ended December 31, 2022 and all future reporting periods, the financial statements reflect Chromocell as a stand-alone entity. For all periods, the Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, realization of long-lived assets, valuation of deferred income taxes, unrealized tax positions and business combination accounting. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2023 and December 31, 2022, the Company did not have any cash equivalents. As of December 31, 2023 and December 31, 2022, the Company did not have any deposits in excess of Federally insured limits. |
Research and Development | Research and Development We incur research and development costs during the process of researching and developing our technologies and future offerings. We expense these costs as incurred unless such costs qualify for capitalization under applicable guidance. The Company reviews acquired R&D and licenses to determine if they should be capitalized or expensed under U.S. GAAP standards. Below is a disaggregation of R&D expenses: For the Year Ended For the Year Ended December 31, 2023 December 31, 2022 Consultant $ 68,900 $ 86,802 Lab Gas — 13,871 Lab Cell Storage 48,572 62,197 Chemistry Manufacturing and Controls (“CMC”) — 3,800 IP Services 2,461,946 225,060 Total $ 2,579,418 $ 391,730 |
Fair Value Measurements and Fair Value of Financial Instruments | Fair Value Measurements and Fair Value of Financial Instruments The Company adopted FASB ASC Topic 820, Fair Value Measurements (“ASC Topic 820”). ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: ● Level 1 Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. ● Level 2 Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. ● Level 3 Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820. Due to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the balance sheet dates. |
Stock-Based Compensation | Stock-Based Compensation The Company accounts for stock-based compensation costs under the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock-based compensation expense recognized includes the compensation cost for all stock-based payments granted to employees, officers, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC 718 is also applied to awards modified, repurchased, or cancelled during the periods reported. Stock-based compensation is recognized as expense over the employee’s requisite vesting period and over the nonemployee’s period of providing goods or services. Pursuant to ASC 718, the Company can elect to either recognize the expenses on a straight-line or graded basis and has elected to do so under the straight-line basis. |
Basic and Diluted Net Loss per Common Share | Basic and Diluted Net Loss per Common Share Basic loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As of December 31, 2023, 197,560 stock options were excluded from dilutive earnings per share as their effects were anti-dilutive. |
Income Taxes | Income Taxes The Company accounts for income taxes pursuant to the provision of ASC 740 “Accounting for Income Taxes,” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized. The Company follows the provision of the ASC 740 related to Accounting for Uncertain Income Tax Position. When tax returns are filed, it is more likely than not that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is most likely that not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions will more likely than not be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits. The federal and state income tax returns of the Company are subject to examination by the Internal Revenue Service and state taxing authorities, generally for three years after they were filed. The Company is in the process of filing the tax returns for the 2023 year. After review of the prior year financial statements and the results of operations through December 31, 2023, the Company has recorded a full valuation allowance on its deferred tax asset. |
Recently Adopted Accounting Pronouncements | Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which was codified in Accounting Standards Codification (“ASC”) 326, Financial Instruments — Credit Losses (“ASC 326”). The standard changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. Because the Company is a smaller reporting company based on the most recent determination as of November 15, 2019, ASC 326 became effective for the Company for fiscal years beginning after December 15, 2022. As such, the Company adopted ASC 326 effective January 1, 2023, utilizing the modified retrospective transition method. Upon adoption, the Company updated its impairment model to utilize a forward-looking current expected credit losses (“CECL”) model in place of the incurred loss methodology for financial instruments measured at amortized cost, primarily including its accounts receivable and contract asset. In relation to available-for-sale (“AFS”) debt securities, the guidance eliminates the concept of “other-than-temporary” impairment, and instead focuses on determining whether any impairment is a result of a credit loss or other factors. The adoption of ASC 326 did not have a material impact on our financial statements as of the adoption date. In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature and convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt and will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that is within the scope of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and treasury stock method will be no longer available. ASU 2020-06 is applicable for fiscal years beginning after December 15, 2022, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The adoption of this ASU did not have a material effect on the Company’s financial statements. |
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity’s effective tax rate reconciliation, as well as information related to income taxes paid to enhance the transparency and decision usefulness of income tax disclosures. This ASU will be effective for the annual period ending December 31, 2025. The Company is currently evaluating the timing and impacts of adoption of this ASU. |
Subsequent Events | Subsequent Events The Company has evaluated all transactions through the date the financial statements were issued for subsequent event disclosure consideration. |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Below is a disaggregation of R&D expenses: | Below is a disaggregation of R&D expenses: For the Year Ended For the Year Ended December 31, 2023 December 31, 2022 Consultant $ 68,900 $ 86,802 Lab Gas — 13,871 Lab Cell Storage 48,572 62,197 Chemistry Manufacturing and Controls (“CMC”) — 3,800 IP Services 2,461,946 225,060 Total $ 2,579,418 $ 391,730 |
STOCKHOLDERS_ EQUITY (Tables)
STOCKHOLDERS’ EQUITY (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
During the year ended December 31, 2023, the fair value of each stock option granted was estimated using the Black-Scholes Option Pricing Model using the following inputs: | During the year ended December 31, 2023, the fair value of each stock option granted was estimated using the Black-Scholes Option Pricing Model using the following inputs: Exercise price $ 22.68 Expected dividend yield 0 % Risk free interest rate 3.50 3.93 % Expected life in years 10 Expected volatility 157 158 % |
Schedule the fair value of the Company’s intellectual property | Schedule the fair value of the Company’s intellectual property Value of intellectual property $ 44.8 Common shares outstanding (as converted) 1,187,302 Value per common share $ 37.71 Illiquidity discount 20 % Minority discount 20 % Fair value of the common stock $ 22.68 |
The following is an analysis of the stock option grant activity: | The following is an analysis of the stock option grant activity: Weighted Weighted Number Exercise Price Remaining Stock Options Outstanding December 31, 2022 50,002 $ 22.68 9.76 Granted 158,670 $ 22.68 9.16 Expired (11,112 ) $ 22.68 — Exercised — $ — — Outstanding December 31, 2023 197,560 $ 22.68 9.08 Exercisable December 31, 2023 84,131 $ 22.68 8.98 A summary of the status of the Company’s nonvested options as of December 31, 2023, and changes during the year ended December 31, 2023, is presented below: Non-vested Options Options Weighted- Non-vested at December 31, 2022 45,556 $ 22.68 Granted 158,670 $ 22.68 Vested (90,797 ) $ 22.68 Forfeited — $ — Non-vested at December 31, 2023 113,429 $ 22.68 |
INCOME TAX (Tables)
INCOME TAX (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows: | A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows: 2023 2023 Income taxes at U.S. statutory rate 19.11 % 19.11 % Income taxes at state rate 9.00 % 9.00 % Change in valuation allowance (28.11 )% (28.11 )% Total provision for income taxes — % — % |
The significant components of the Company’s deferred tax assets and liabilities as of December 31, 2023 and 2022 are comprised of the following: | Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company’s deferred tax assets and liabilities as of December 31, 2023 and 2022 are comprised of the following: December 31, 2023 2022 Deferred tax assets Net operating loss carryforwards $ 2,248,163 $ 1,763,875 Stock-based compensation 518,174 30,962 Accrued compensation 181,576 62,369 Capitalized organizational costs 22,016 — Capitalized intellectual property costs 620,440 — Interest expense limitation 36,202 — Total deferred tax assets 3,626,571 1,857,206 Valuation allowance (3,626,571 ) (1,857,206 ) Net deferred tax assets — — Deferred tax liabilities Total deferred tax liabilities — — Net deferred taxes $ — $ — |
ORGANIZATION AND NATURE OF BU_2
ORGANIZATION AND NATURE OF BUSINESS (Details Narrative) - $ / shares | 12 Months Ended | ||
Feb. 21, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||
Sale of stock, description of transaction | the Company completed the initial public offering of its Common Stock (the “IPO”) and issued and sold 1,100,000 shares of Common Stock at a price to the public of $6.00 per share. The aggregate net proceeds from the IPO were approximately $5.7 million after deducting underwriting discounts and commissions and offering expenses. | in consideration therefor, the Company would issue upon close of the IPO, and regardless of whether the Company would have issued any shares of Series B Preferred Stock, an aggregate of 4,167 shares (such shares, the “Standby Shares”) of Common Stock to the Standby Investor (such agreement, the “Series B Securities Purchase Agreement”). | |
Issued and sold shares of Common Stock | 1,100,000 | 3,914,338 | 1,111,112 |
Common stock price (per share) | $ 6 |
GOING CONCERN ANALYSIS (Details
GOING CONCERN ANALYSIS (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Net Income (Loss) Attributable to Parent | $ 7,380,793 | $ 2,458,589 |
Cash | 96,391 | 55,074 |
Cash and cash equivalents | 100,000 | 100,000 |
Working capital deficit | $ 6,400,000 | $ 3,700,000 |
Below is a disaggregation of R&
Below is a disaggregation of R&D expenses: (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Product Information [Line Items] | ||
Research and development expense | $ 2,579,418 | $ 391,730 |
Consultant [Member] | ||
Product Information [Line Items] | ||
Research and development expense | 68,900 | 86,802 |
Lab Gas [Member] | ||
Product Information [Line Items] | ||
Research and development expense | 13,871 | |
Lab Cell Storage [Member] | ||
Product Information [Line Items] | ||
Research and development expense | 48,572 | 62,197 |
Chemistry Manufacturing And Controls [Member] | ||
Product Information [Line Items] | ||
Research and development expense | 3,800 | |
IP Services [Member] | ||
Product Information [Line Items] | ||
Research and development expense | $ 2,461,946 | $ 225,060 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) | Feb. 14, 2024 | Aug. 02, 2023 | Jan. 10, 2023 | Dec. 06, 2022 | Dec. 31, 2023 | Dec. 31, 2022 |
Employment Agreement | Pursuant to such agreement, Mr. Kopfli agreed to serve as the Company’s Chief Executive Officer and Vice-Chairman of its Board of Directors (the “Board”) in consideration for an annualized salary of $275,000, payable in cash at the rate of $5,000 per month (a minimum of $1,125 per week), with the remainder accrued and paid as of the earliest of a sale or liquidation of the Company, the Company’s bankruptcy or three days after the approval by the Board of a funded budget with appropriately established milestones subsequent to the effective date of a Form S-1 registration statement (“Post-registration Approval”). Mr. Kopfli also agreed, as of Post-registration Approval, to resign as Chief Executive Officer of Chromocell Corporation although he may continue service on the Board of Directors of Chromocell Corporation, including as its Board Chairperson. The employment agreement provides that Mr. Kopfli receive an option to acquire 22,223 shares of the Company’s common stock | |||||
Demand letter from an attorney | the Board received a demand letter from an attorney representing Chromocell Holdings and Mr. Kopfli. Mr. Kopfli alleges an improper termination for “cause” and seeks monetary damages in connection therewith in the amount of $479,169. Of the $479,169 asserted by Mr. Kopfli, as of December 31, 2023, the Company has accrued $363,091 in compensation expenses associated with Mr. Kopfli’s prior employment with the Company. To the extent Mr. Kopfli is successful in his assertions, the Company will pay any amounts owed thereunder from future working capital reserves; however, the Company believe the assertions made by Mr. Kopfli are without merit and intend to vigorously defend the matter. | |||||
Director Note | the Company and Mr. Todd Davis, one of the Company’s directors, entered into the Director Note for $175,000. The Director Note has an original issuance discount of $75,000, and matures on December 31, 2023, or, if earlier to occur, upon the closing of an underwritten offering of securities resulting in at least $15 million in gross proceeds. | |||||
Due to Chromocell Corporation | $ 5,386 | $ 5,386 | ||||
Side letter to the contribution agreement | the Company entered into a side letter to the Contribution Agreement (the “Holdings Side Letter”) with Chromocell Holdings. Pursuant to the side letter, upon closing of the Company’s IPO: (a) Chromocell Holdings re-assumed all $1.6 million in direct liabilities previously assumed by the Company in accordance with the Contribution Agreement, (b) Chromocell Holdings waived the Company’s obligations to make a cash payment in the amount of $0.6 million to Chromocell Holdings, and (c) in consideration thereof, the Company issued to Chromocell Holdings 2,600 shares of Series C Convertible Redeemable Preferred Stock of the Company, par value of $0.0001 per share (the “Series C Preferred Stock”). | |||||
Series C Preferred Stock [Member] | ||||||
Liquidation preference Series C Convertible Redeemable Preferred Stock (per share) | $ 1,000 | $ 0.001 | $ 0.001 |
NOTES PAYABLE (Details Narrativ
NOTES PAYABLE (Details Narrative) - USD ($) | 12 Months Ended | ||||||||||||||
Nov. 13, 2023 | Oct. 10, 2023 | Jun. 23, 2023 | Apr. 17, 2023 | Feb. 27, 2023 | Dec. 06, 2022 | Feb. 04, 2022 | Aug. 17, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Feb. 21, 2024 | Jan. 30, 2024 | Nov. 22, 2023 | Oct. 12, 2023 | Aug. 17, 2023 | |
Debt Instrument [Line Items] | |||||||||||||||
Note payable | $ 450,000 | ||||||||||||||
Discount issued | $ 150,000 | $ 188,119 | $ 140,430 | ||||||||||||
Interest rate | 50% | ||||||||||||||
Maturity date | Feb. 03, 2023 | ||||||||||||||
Interest expense | $ 14,370 | $ 135,630 | |||||||||||||
Note agreement was amended | the Investor Note agreement was amended. The maturity date was extended from its original due date of February 3, 2023 to May 15, 2023, in return for the Company agreeing to pay 2% per month in accrued interest and the third party agreeing to settle its outstanding debt, including accrued interests in shares of common stock at the IPO. Accrued interest and related interest expense totaled $98,056 for the years ended December 31, 2023, compared to $0 for year ended December 31, 2022. | ||||||||||||||
Note agreement was amended | in consideration therefor, issued to such holder 50,000 shares of common stock. The Company determined that this extension qualified as a modification of the Investor Note rather than an extinguishment. The Company recorded an expense of $126,000 from the issuance of the 556 shares of common stock based on a share price of $22.68. The $22.68 share price was based on a third-party valuation of the company’s common stock, with certain adjustments as set forth below in detail in Note 7 – Stockholders’ Equity. This expense was recorded to interest expense on the Company’s statement of operations for the year ended December 31, 2023. | ||||||||||||||
Common Stock, Shares, Issued | 3,914,338 | 1,111,112 | 1,100,000 | ||||||||||||
IPO [Member] | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Common Stock, Shares, Issued | 2,533,853 | ||||||||||||||
Subsequent Event [Member] | IPO [Member] | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Common Stock, Shares, Issued | 1,100,000 | ||||||||||||||
Investor Note [Member] | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Common Stock, Shares, Issued | 3,334 | 3,334 | 30,000 | ||||||||||||
Face amount | $ 450,000 | ||||||||||||||
Resale shares of common stock | In addition, pursuant to the Investor Note Side Letters, the Company agreed to register the 8,890 shares of Common Stock (5,556 issued for the June 23, 2023 side letter, and 3,334 issued for the August 17, 2023 side letter) for resale. The Company recorded an expense of $75,600 from the issuance of the 3,333 shares of common stock based on a share price of $22.68. The $22.68 share price was based on a third-party valuation of the company’s common stock, with certain adjustments | ||||||||||||||
Interest expense | $ 75,600 | $ 75,600 | |||||||||||||
Share price | $ 22.68 | $ 22.68 | |||||||||||||
Investor Note [Member] | Subsequent Event [Member] | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Common Stock, Shares, Issued | 77,778 | ||||||||||||||
Director Note [Member] | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Discount issued | $ 72,000 | ||||||||||||||
Interest expense | 75,000 | ||||||||||||||
Notes Payable | 175,000 | ||||||||||||||
Underwritten offering of securities | $ 15,000,000 | ||||||||||||||
Bridge Loan [Member] | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Note agreement was amended | the Company entered into a bridge loan for working capital purposes, with various accredited investors, all of whom are pre-existing stockholders, in the aggregate principal amount of $393,808 (the “April Bridge Financing”). During the three months ended March 31, 2023, the Company received $166,903 in Advances from certain participating investors. Such Advances accrued interest at a rate of 8% per annum until close of the April Bridge Financing on April 17, 2023, for a total of $1,870 in aggregate interest on all Advances. | ||||||||||||||
Aggregate principal amount | $ 198,128 | ||||||||||||||
Promissory Note [Member] | IPO [Member] | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Aggregate face amount | $ 210,000 | ||||||||||||||
Aggregate purchase price | $ 175,000 |
During the year ended December
During the year ended December 31, 2023, the fair value of each stock option granted was estimated using the Black-Scholes Option Pricing Model using the following inputs: (Details) | 12 Months Ended |
Dec. 31, 2023 $ / shares | |
Offsetting Assets [Line Items] | |
Exercise price | $ 22.68 |
Equity Option [Member] | |
Offsetting Assets [Line Items] | |
Exercise price | $ 22.68 |
Expected dividend yield | 0% |
Expected option life (in years) | 10 years |
Equity Option [Member] | Minimum [Member] | |
Offsetting Assets [Line Items] | |
Risk-free interest rate | 3.50% |
Expected volatility | 157% |
Equity Option [Member] | Maximum [Member] | |
Offsetting Assets [Line Items] | |
Risk-free interest rate | 3.93% |
Expected volatility | 158% |
Schedule the fair value of the
Schedule the fair value of the Company’s intellectual property (Details) - USD ($) $ / shares in Units, $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 | Aug. 10, 2022 |
Equity [Abstract] | |||
Value of intellectual property | $ 44.8 | ||
Common shares outstanding (as converted) | 3,914,338 | 1,111,112 | 1,187,302 |
Value per common share | $ 0.001 | $ 0.001 | $ 37.71 |
Illiquidity discount | 2,000% | ||
Minority discount | 2,000% | ||
Fair value of the common stock | $ 22.68 |
The following is an analysis of
The following is an analysis of the stock option grant activity: (Details) | 12 Months Ended |
Dec. 31, 2023 $ / shares shares | |
Equity [Abstract] | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance | shares | 50,002 |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance | $ 22.68 |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Life | 9 years 9 months 3 days |
Granted | shares | 158,670 |
Granted | $ 22.68 |
Granted | 9 years 1 month 27 days |
Expired | shares | (11,112) |
Expired | $ 22.68 |
Exercised | shares | |
Exercised | |
Outstanding December 31, 2023 | shares | 197,560 |
Outstanding December 31, 2023 | $ 22.68 |
Outstanding December 31, 2023 | 9 years 29 days |
Exercisable December 31, 2023 | shares | 84,131 |
Exercisable December 31, 2023 | $ 22.68 |
Exercisable December 31, 2023 | 8 years 11 months 23 days |
Non-vested at December 31, 2022 | shares | 45,556 |
Non-vested at December 31, 2022 | $ 22.68 |
Granted | $ 22.68 |
Vested | shares | (90,797) |
Vested | $ 22.68 |
Forfeited | shares | |
Forfeited | |
Non-vested at December 31, 2023 | shares | 113,429 |
Non-vested at December 31, 2023 | $ 22.68 |
STOCKHOLDERS_ EQUITY (Details N
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($) | 12 Months Ended | ||||||||||
Feb. 21, 2024 | Nov. 22, 2023 | Jun. 22, 2023 | May 15, 2023 | Apr. 17, 2023 | Mar. 09, 2023 | Jan. 10, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Oct. 11, 2023 | Aug. 10, 2022 | |
Class of Stock [Line Items] | |||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited | 1,203,704 | ||||||||||
Sale of stock, description of transaction | the Company completed the initial public offering of its Common Stock (the “IPO”) and issued and sold 1,100,000 shares of Common Stock at a price to the public of $6.00 per share. The aggregate net proceeds from the IPO were approximately $5.7 million after deducting underwriting discounts and commissions and offering expenses. | in consideration therefor, the Company would issue upon close of the IPO, and regardless of whether the Company would have issued any shares of Series B Preferred Stock, an aggregate of 4,167 shares (such shares, the “Standby Shares”) of Common Stock to the Standby Investor (such agreement, the “Series B Securities Purchase Agreement”). | |||||||||
Common Stock, Shares, Issued | 1,100,000 | 3,914,338 | 1,111,112 | ||||||||
Company's intellectual property | $ 44,800,000 | ||||||||||
Common shares outstanding (as converted) | 3,914,338 | 1,111,112 | 1,187,302 | ||||||||
Value per common share | $ 0.001 | $ 0.001 | $ 37.71 | ||||||||
Total number of options granted | 197,560 | 0 | |||||||||
Exercise price for options | $ 22.68 | ||||||||||
Intrinsic value | $ 0 | ||||||||||
Option vesting amortization | 1,733,233 | $ 110,146 | |||||||||
Unamortized stock option expense | $ 1,854,280 | ||||||||||
Period for the unamortized stock compensation | 2 years 10 months 28 days | ||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Description | the Company and Camden Capital LLC amended and restated the Consultant Agreement by entering into an Amended and Restated Consultant Agreement, whereby the RSU for 16,667 shares of common stock was cancelled, and the Company agreed to grant Camden Capital LLC an option to acquire 27,778 shares of common stock within 30 days of the closing of the IPO. As of June 23, 2023, such RSU for 16,667 shares of common stock had not vested, and no expense was recorded on the Company’s financial statements. | ||||||||||
Options Held [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Company granted options to acquire description | the Company granted options to acquire 50,002 shares of the Company’s common stock to employees and consultants of the Company pursuant to their employment or consulting agreements. These options had a grant date fair value of $1,122,244. These options have an exercise price of $22.68, a term of 10 years, and vest quarterly over ten quarters, with such vesting commencing on October 1, 2022. | ||||||||||
IPO [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Common Stock, Shares, Issued | 2,533,853 | ||||||||||
Demutualization by Insurance Entity, Securities Issued, Amount of Net Proceeds | $ 255,412 | ||||||||||
IPO [Member] | Options Held [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Company granted options to acquire description | the Company granted an option to acquire 2,778 shares of the Company’s common stock to a consultant of the Company pursuant to their consulting agreements. This option had a grant date fair value of $62,336. This option has an exercise price of $22.68, a term of 10 years, and vests upon the IPO or sale of the Company. | ||||||||||
Common Stock [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Common Stock at a price per whole share | $ 0.1008 | ||||||||||
Common Stock [Member] | Options Held [Member] | Director [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Company granted options to acquire description | the Company issued an option to acquire 24,223 shares of the Company’s common stock to a director, pursuant to their continued service as a director. This option had a grant date fair value of $543,306. This option has an exercise price of $22.68, a term of 10 years, and will vest over 3 years. | the Company issued an option to acquire 15,000 shares of the Company’s common stock to a director, pursuant to their continued service as a director. This option had a grant date fair value of $336,606. This option has an exercise price of $22.68, a term of 10 years, and will vest over 2.25 years commencing on March 9, 2023. | |||||||||
Common Stock [Member] | IPO [Member] | Options Held [Member] | Director [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Company granted options to acquire description | the Company issued an option to acquire 27,778 shares of the Company’s common stock to a director, pursuant to their continued service as a director. This option had a grant date fair value of $623,057. This option has an exercise price of $22.68, a term of 10 years, and vests upon the IPO or sale of the Company. | ||||||||||
Series B Preferred Stock [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Shaes issue to investor | 0 | 0 | 750 | ||||||||
Shaes par value | $ 0.001 | $ 0.001 | $ 0.0001 | ||||||||
Purchase price of shares | $ 1,000 | ||||||||||
Series A Preferred Stock [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Shaes issue to investor | 600,000 | 600,000 | |||||||||
Shaes par value | $ 0.001 | $ 0.001 | |||||||||
conversion of the series A convertible preferred stock | 600,000 |
LICENSE AGREEMENT (Details Narr
LICENSE AGREEMENT (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 23, 2023 | Dec. 31, 2023 | |
License Agreement | ||
Benuvia License Agreement | the Company agreed to pay Benuvia a 6.5% royalty on net sales of the Spray Formulations for a period of up to 15 years from the date of the first commercial sale of any of the Spray Formulations. In addition, on December 23, 2023, the Company entered into a stock issuance agreement with Benuvia pursuant to which the Company agreed to issue Benuvia 384,226 shares of the Company’s Common Stock. | |
Shares issued for license | 384,226 | |
Licensing expenses | $ 2,200,000 |
A reconciliation of income tax
A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows: (Details) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | ||
Income taxes at U.S. statutory rate | 19.11% | 19.11% |
Income taxes at state rate | 9% | |
Change in valuation allowance | (28.11%) | |
Total provision for income taxes |
The significant components of t
The significant components of the Company’s deferred tax assets and liabilities as of December 31, 2023 and 2022 are comprised of the following: (Details) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Deferred tax assets | ||
Net operating loss carryforwards | $ 2,248,163 | $ 1,763,875 |
Stock-based compensation | 518,174 | 30,962 |
Accrued compensation | 181,576 | 62,369 |
Capitalized organizational costs | 22,016 | |
Capitalized intellectual property costs | 620,440 | |
Interest expense limitation | 36,202 | |
Total deferred tax assets | 3,626,571 | 1,857,206 |
Valuation allowance | (3,626,571) | (1,857,206) |
Net deferred tax assets | ||
Deferred tax liabilities | ||
Total deferred tax liabilities | ||
Net deferred taxes |
INCOME TAX (Details Narrative)
INCOME TAX (Details Narrative) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Income Tax Disclosure [Abstract] | ||
Valuation allowance | $ 3,626,571 | $ 1,857,206 |
Operating loss carryforward | $ 8,000,000 |
SUBSEQUENT EVENTS (Details Narr
SUBSEQUENT EVENTS (Details Narrative) - USD ($) $ / shares in Units, $ in Millions | Feb. 29, 2024 | Feb. 08, 2024 | Feb. 21, 2024 | Dec. 31, 2023 | Nov. 22, 2023 | Dec. 31, 2022 | Aug. 10, 2022 |
Subsequent Event [Line Items] | |||||||
Common stock, shares issued | 1,100,000 | 3,914,338 | 1,111,112 | ||||
Shares of common stock per share | $ 0.001 | $ 0.001 | $ 37.71 | ||||
Subsequent Event [Member] | Common Class A [Member] | Bridge Financing Note Amendments and Recission Agreement [Member] | |||||||
Subsequent Event [Line Items] | |||||||
Subsequent description | On February 10, 2024, the Company entered into a Stock Rescission Agreement with certain affiliates of A.G.P. (the “Stock Rescission Agreement” and, together with the Bridge Financing Note Amendments, the “Representative Affiliate Transactions”), pursuant to which the Company rescinded 111,129 shares of Common Stock held by such affiliates of A.G.P. and agreed to refund an aggregate of $91,513 paid by such affiliates of A.G.P. in consideration therefor within 30 days of the effective date of the Stock Rescission Agreement. | ||||||
Subsequent Event [Member] | Common Class A [Member] | Amendment To Investor Note [Member] | |||||||
Subsequent Event [Line Items] | |||||||
Subsequent description | in consideration therefor, agreed to issue to such Holder of the Investor Note 77,778 shares of Common Stock on the earlier to occur of the IPO or February 29, 2024. | ||||||
IPO [Member] | |||||||
Subsequent Event [Line Items] | |||||||
Common stock, shares issued | 2,533,853 | ||||||
IPO [Member] | Subsequent Event [Member] | |||||||
Subsequent Event [Line Items] | |||||||
Common stock, shares issued | 1,100,000 | ||||||
Shares of common stock per share | $ 6 | ||||||
Net proceeds from the IPO | $ 5.7 |